Amino Acid, Peptide, or Protein – Page 3 – Talk Bio

Actionable Insights Powered by AI

FDA Requests Eli Lilly and Novo Nordisk to Remove Suicide Warnings from GLP-1 Drug Labels

2 weeks ago talkbio0Tagged eli lilly, Glucagon-Like Peptide 1, Saxenda, suicide warnings, United States Food and Drug Administration, Wegovy, Zepbound

FDA; GLP-1; suicide warnings; Eli Lilly; Novo Nordisk; Wegovy; Zepbound; Saxenda

Novo Nordisk Refocuses on Diabetes and Obesity to Expand GLP-1 Market at JPM26

2 weeks ago talkbio0Tagged Diabetes, Glucagon-Like Peptide 1, JPM26, Mike Doustdar, Novo Nordisk, Obesity, semaglutide, Wegovy pill

Novo Nordisk; diabetes; obesity; GLP-1; JPM26; Mike Doustdar; Wegovy pill; semaglutide

JPM26: Novo Nordisk and Eli Lilly Compete Fiercely in Oral Obesity Treatments

2 weeks ago talkbio0Tagged eli lilly, JPM26, JPMHC, Novo Nordisk, oral obesity drugs, orglipron, semaglutide

Novo Nordisk; Eli Lilly; oral obesity drugs; JPM26; JPMHC; orglipron; semaglutide

Merck Raises Long-Term Revenue Outlook to $70 Billion by Mid-2030s

2 weeks ago talkbio0Tagged growth drivers, Keytruda, Merck, mid-2030s, revenue target

Merck; revenue target; $70 billion; mid-2030s; Keytruda; new growth drivers

FDA Requests Flu Vaccine Label Updates for Febrile Seizure Risk in Young Children

2 weeks ago talkbio0Tagged Child, Febrile Convulsions, Influenza virus vaccine, Labels (device), United States Food and Drug Administration, update, Vaccines

FDA; flu vaccine; febrile seizures; label update; children; influenza vaccine

Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting Durable Complete Response and 66.7% ORR in Advanced GC/GEJ

3 weeks ago talkbio0Tagged ASCO GI 2026, CAR-T, Claudin-18 Isoform A2, IMC002, Immunofoco, In complete remission, Malignant neoplasm of stomach, ORR

Immunofoco; IMC002; ASCO GI 2026; CAR-T; CLDN18.2; gastric cancer; complete response; ORR

AbbVie Pays $650M Upfront to RemeGen for PD-1/VEGF Bispecific RC148 Rights Outside China

3 weeks ago talkbio0Tagged AbbVie, Antibodies, Bispecific, Neoplasms, PD-1/VEGF, RC148, RemeGen

AbbVie; RemeGen; RC148; PD-1/VEGF; bispecific antibody; oncology; licensing deal; $650M; $5.6B

BioNTech and UPenn Launch $50M Seed Fund for Early-Stage Biotechs

3 weeks ago talkbio0Tagged BioNTech, biotech startups, methionine, RNA, Messenger, seed fund, UPenn

BioNTech; UPenn; seed fund; $50M; mRNA; biotech startups

Enliven’s Phase 1b ELVN‑001 leukemia pill shows competitive efficacy vs. Novartis and Terns CML TKIs

3 weeks ago talkbio0Tagged asciminib, BCR-ABL1, Contraceptives, Oral, Deep molecular response, ELVN-001, ENABLE trial, Enliven Therapeutics, Inhibitor, Measles-Mumps-Rubella Vaccine, Molecular Response, Myeloid Leukemia, Chronic, Novartis, Phase 1b, Protein-tyrosine kinase inhibitor, T315I, TERN-701, Terns, TKI, WDR20 gene

Enliven Therapeutics; ELVN-001; Phase 1b; chronic myeloid leukemia; CML; BCR-ABL1 inhibitor; major molecular response; MMR; deep molecular response; DMR; asciminib; Novartis; Terns Pharmaceuticals; TERN-701; T315I; ENABLE trial; CML pill; tyrosine kinase inhibitor; TKI; best-in-class

Obesity biotech Alveus raises ~$160M Series A to advance MariTide‑like GLP‑1/GIPR drug and amylin pipeline

3 weeks ago talkbio0Tagged * * New Rhein Healthcare Investors, * * Sanofi Capital, ALV-100, ALV-200, Alveus Therapeutics, Amylin, Andera Partners, Antagonist muscle action, GIPR gene, MariTide-like, Metabolic Diseases, Obesity, Omega Funds, Product containing glucagon-like peptide 1 receptor agonist (product), Series

Alveus Therapeutics; obesity biotech; $160 million Series A; ALV-100; MariTide-like; GLP-1 receptor agonist; GIPR antagonist; amylin; ALV-200; obesity drugs; metabolic diseases; Sanofi Capital; New Rhein Healthcare Investors; Andera Partners; Omega Funds